Drug Profile
Esmethadone - Relmada Therapeutics
Alternative Names: +-Methadone - Relmada Therapeutics; 6S-Methadone - Relmada Therapeutics; d Methadone - Relmada Therapeutics; Dextromethadone - Relmada Therapeutics; Esmethadone hydrochloride - Relmada Therapeutics; REL 1017; S-(+)-methadone; S-Methadone - Relmada TherapeuticsLatest Information Update: 15 Jan 2024
Price :
$50
*
At a glance
- Originator Cornell University
- Developer Relmada Therapeutics
- Class Analgesics; Antidepressants; Antipsychotics; Drug withdrawal therapies; Eye disorder therapies; Ketones; Small molecules
- Mechanism of Action NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Major depressive disorder
- Discontinued Eye disorders; Mitochondrial disorders; Neuropathic pain; Rett syndrome
Most Recent Events
- 15 Jan 2024 Discontinued - Phase-I for Neuropathic pain (In volunteers) in Canada (PO) before January 2024 (Relmada Therapeutics pipeline, January 2024)
- 15 Jan 2024 Discontinued - Preclinical for Eye disorders in USA (PO) before January 2024 (Relmada Therapeutics pipeline, January 2024)
- 15 Jan 2024 Discontinued - Preclinical for Mitochondrial disorders in USA (PO) before January 2024 (Relmada Therapeutics pipeline, January 2024)